A cluster of evidence is tightening the diagnostic toolbox in urologic oncology. A new review argues that liquid biopsy is becoming a non-invasive route to precision treatment decisions in bladder cancer, while a separate retrospective study evaluates how PSMA SPECT/CT staging information can refine which patients benefit most. Together, the findings point to faster molecularly informed triage without relying solely on tissue sampling or conventional imaging.